Arthritis Drug Of Japan’s Chugai, Roche Shows Well In Phase III Trial
This article was originally published in PharmAsia News
A drug developed by Japan's Chugai Pharmaceutical and Switzerland's Roche Holdings is showing favorable results midway through a Phase III study for reducing joint damage from rheumatoid arthritis. The drug is Actemra (tocilizumab), the subject of a delay by the U.S. FDA in reviewing it for possible approval. FDA wanted more data related to manufacturing and labeling, according to Roche. Researchers said the ongoing study shows Actemra to be effective in slowing the progression of bone erosion when used over a four-week period with methotrexate. The drug is expected to be a billion-dollar seller for the two drug makers once approved. (Click here for more
You may also be interested in...
The German pricing and reimbursement system has been successful in recognizing the value and uniqueness of orphan drugs.
Erectile problems prevent a quarter of Brits from being intimate with a partner. Viatris' Upjohn - which markets Viagra Connect in the UK - is working with the Men’s Health Forum, sexual health charity Brook and dating expert Sarah Louise Ryan raise awareness of the problem and get men talking about the issue with their partners and with healthcare professionals.
Medtechs took a long look at themselves as they rose to the challenges of COVID-19. How they responded, repurposed and regrouped to tackle the coronavirus was both sobering and uplifting. The lessons of 2020 must be integrated into the digitally-enabled health care systems of 2021 and beyond.